Alimera Sciences Stock Price, News & Analysis

Alimera Sciences (Nasdaq: ALIM) announced an agreement with Jaeb Center for Health Research to conduct a clinical trial evaluating ILUVIEN versus observation in preventing vision loss from radiation retinopathy. The trial will involve 600 participants receiving plaque brachytherapy for choroidal melanoma, beginning in Q1 2023. The study aims to prevent or reduce macular edema and vision complications following radiation therapy. Notably, ILUVIEN is already approved for treating diabetic macular edema and has shown promising outcomes in other indications.

Alimera Sciences has received unrestricted reimbursement approval for its ILUVIEN implant in Ireland, aimed at treating non-infectious uveitis affecting the posterior segment of the eye. The Health Service Executive and National Centre for Pharmacoeconomics granted this approval, expanding the availability of ILUVIEN across all direct and key distributor markets. ILUVIEN's sustained-release technology allows for reduced disease recurrence, benefiting patients with fewer injections.

Alimera Sciences announces the presentation of positive findings from the RIVER study during the EURETINA 2022 congress in Germany. More than 20 scientific abstracts related to ILUVIEN® (fluocinolone acetonide intravitreal implant) will be showcased, reinforcing its efficacy in treating diabetic macular edema (DME). ILUVIEN is known for its continuous microdosing technology, providing a sustained release for up to 36 months. The product is approved in multiple regions, including the U.S. and various European countries, for patients who have not had a significant rise in intraocular pressure.

Alimera Sciences (Nasdaq: ALIM), a global pharmaceutical firm focused on retinal health, announced that CEO Rick Eiswirth will present at the HC Wainwright 2nd Annual Ophthalmology Conference on August 17, 2022. The presentation will be available on demand starting at 7:00 AM ET. Additionally, Alimera's management will hold one-on-one meetings with registered investors during the conference. This engagement highlights Alimera's commitment to enhancing vision care and its ongoing relationship with the investment community.

Alimera Sciences has received reimbursement approval without label restrictions for its ILUVIEN® (fluocinolone acetonide) implant in Portugal, as granted by INFARMED. The company plans to launch the product in Q3 2022, expanding its market presence in treating non-infectious uveitis affecting the posterior segment.

CEO Rick Eiswirth stated that this marks a significant step in making ILUVIEN accessible to patients across various markets, enhancing treatment options for chronic inflammatory conditions.

Alimera Sciences (Nasdaq: ALIM) reported second quarter 2022 financial results showing a consolidated net product revenue of $14.6 million, a 36% increase from Q2 2021. U.S. net product revenue rose 53%, driven by increased physician access and patient flow. However, total consolidated net revenue fell 33% due to prior licensing revenue. The company experienced a net loss of $3.1 million and had cash and equivalents of $7.9 million as of June 30, 2022. Alimera expects growth from ILUVIEN’s new pricing and reimbursement in Spain, Italy, and France.

Alimera Sciences recently presented promising data from the PALADIN Phase 4 Study at the ASRS conference, highlighting the effectiveness of ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg in treating diabetic macular edema (DME). The study confirms ILUVIEN's safety and its ability to reduce treatment frequency while enhancing visual acuity. Key findings include an average vision gain of 4.5 ETDRS letters post-treatment and reduced retinal thickness variability.

All outcomes reflect ILUVIEN's potential as a durable treatment option.

Alimera Sciences (Nasdaq: ALIM) will announce its second quarter financial results on July 27, 2022, before market opening. A conference call will be held at 9:00 AM ET to discuss the results and provide updates on corporate developments. Participants can pre-register for the call via the company's website. A webcast replay will be accessible one hour post-call through October 27, 2022. Alimera is dedicated to improving retinal health and vision.

Alimera Sciences announces the upcoming launch of ILUVIEN in France for treating non-infectious posterior uveitis, partnering with Horus Pharma. This product, which recently received pricing and reimbursement approval, aims to reduce disease recurrence. ILUVIEN is already successful in treating diabetic macular edema and is now expanding to address uveitis, a leading cause of blindness. This launch marks a significant achievement in the company’s European strategy, expanding its market presence in major countries.